The projected cost per box is Rs 2000, which is significantly lower than existing alternatives, claims IIT Guwahati
The projected cost per box is Rs 2000, which is significantly lower than existing alternatives, claims IIT Guwahati|Representational image
NEWS

Positive news on COVID-19 vaccine may come today

I am hearing there will be positive news soon on initial trials of Oxford COVID-19 vaccine that is backed by AstraZeneca, political editor of 'ITV', Robert Peston, said

Team EastMojo

Team EastMojo

A positive announcement on initial trials of the University of Oxford's potential COVID-19 vaccine could be made as soon as Thursday.

University of Oxford's potential COVID-19 vaccine has been licensed to AstraZeneca. Citing a source, the political editor of ITV, Robert Peston said this.

The potential vaccine is already in large-scale Phase III human trials to assess whether it can protect against COVID-19, but its developers have yet to report Phase I results which would show whether it is safe and whether or not it induces an immune response.

The developers of the vaccine said this month they were encouraged by the immune response they had seen in trials so far and were expecting to publish Phase 1 data by the end of July.

More than 100 vaccines are being developed and tested around the world to try to stop the COVID-19 pandemic, which has killed hundreds of thousands and ravaged the global economy.

AstraZeneca's experimental vaccine is probably the world's leading candidate and most advanced in terms of development, the World Health Organisation's chief scientist said in June.

The company has signed agreements with governments around the globe to supply the vaccine should it be cleared for use.

A spokeswoman for Oxford University said that the team was awaiting confirmation from a scientific journal of a publication date and time for the data, but gave no further details. “(We) are not able to confirm when it will be released,” she said.

Peston said in a blog post: “I am hearing there will be positive news soon (perhaps tomorrow) on initial trials of the Oxford COVID-19 vaccine that is backed by AstraZeneca.”

Researchers in the United States reported on Tuesday that Moderna Inc's experimental vaccine showed it was safe and provoked immune responses in all 45 healthy volunteers in an ongoing early-stage study.

Moderna started its Phase II trial in May and expects to start a Phase III trial on July 27.

Seventy-five countries have submitted expressions of interest to protect their populations and those of other nations through joining the COVAX Facility, a mechanism designed to guarantee rapid, fair and equitable access to COVID-19 vaccines worldwide.

The 75 countries, which would finance the vaccines from their own public finance budgets, partner with up to 90 lower-income countries that could be supported through voluntary donations to Gavi’s COVAX Advance Market Commitment (AMC). Together, this group of up to 165 countries represents more than 60% of the world’s population. Among the group are representatives from every continent and more than half of the world’s G20 economies.

For more such stories, follow us on Facebook, Twitter and Instagram. Activate Website Notifications to stay updated.

EastMojo
www.eastmojo.com